Lipum AB (OSTO:LIPUM) Price-to-Tangible-Book : (As of Jun. 04, 2024)

View and export this data going back to 2021. Start your Free Trial

What is Lipum AB Price-to-Tangible-Book?

As of today (2024-06-04), Lipum AB's share price is kr6.85. Lipum AB's Tangible Book per Share of Mar. 2024 for the quarter that ended in Mar. 2024 was kr-0.49. Hence, Lipum AB's Price to Tangible Book Ratio of today is .

The historical rank and industry rank for Lipum AB's Price-to-Tangible-Book or its related term are showing as below:

During the past 5 years, Lipum AB's highest Price to Tangible Book Ratio was 26.06. The lowest was 1.63. And the median was 4.39.

OSTO:LIPUM's Price-to-Tangible-Book is not ranked ^*
in the Biotechnology industry.
Industry Median: 2.81
* Ranked among companies with meaningful Price-to-Tangible-Book only.

A closely related ratio is called PB Ratio. As of today, Lipum AB's share price is kr6.85. Lipum AB's Book Value per Sharefor the quarter that ended in Mar. 2024 was kr-0.49. Hence, Lipum AB's P/B Ratio of today is .

Lipum AB Price-to-Tangible-Book Historical Data

The historical data trend for Lipum AB's Price-to-Tangible-Book can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Lipum AB Price-to-Tangible-Book Chart

Lipum AB Annual Data

Trend

Dec19

Dec20

Dec21

Dec22

Dec23

Price-to-Tangible-Book

3.35

3.81

13.27

Lipum AB Quarterly Data
	Dec19	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Sep23	Dec23	Mar24
Price-to-Tangible-Book	Get a 7-Day Free Trial											3.81	4.49	6.10	13.27	-

Competitive Comparison of Lipum AB's Price-to-Tangible-Book

For the Biotechnology subindustry, Lipum AB's Price-to-Tangible-Book, along with its competitors' market caps and Price-to-Tangible-Book data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Lipum AB's Price-to-Tangible-Book Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Lipum AB's Price-to-Tangible-Book distribution charts can be found below:

* The bar in red indicates where Lipum AB's Price-to-Tangible-Book falls into.

Lipum AB Price-to-Tangible-Book Calculation

Lipum AB's price-to-tangible-book ratio for today is calculated as:

Price to Tangible Book	=	Share Price	/	Tangible Book per Share (Q: Mar. 2024 )
	=	6.85	/	-0.49
	=

It can also be calculated from the numbers for the whole company:

Price to Tangible Book	=	Market Cap	/	Tangible Equity
	=	Market Cap	/	(Total Stockholders Equity	-	Preferred Stock	-	Intangible Assets)

A closely related ratio is called PB Ratio. The difference between Price-to-Tangible-Book Ratio and PB Ratio is that book value other than intangibles are used in the calculation.

Be Aware

Some businesses have very light assets, such as software companies or insurance agencies. The Price-to-Book Ratio does not work well for these companies. Some companies even have negative equity, so the Price-to-Book Ratio cannot be applied to them.

Lipum AB Price-to-Tangible-Book Related Terms

Thank you for viewing the detailed overview of Lipum AB's Price-to-Tangible-Book provided by GuruFocus.com. Please click on the following links to see related term pages.

Lipum AB (OSTO:LIPUM) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Lipum AB (OSTO:LIPUM) » Definitions » Price-to-Tangible-Book

Comparable Companies

Traded in Other Exchanges

N/A

Address

Tvistevagen 48 C, Umea, SWE, 907 36

Website

https://www.lipum.se

Lipum AB is a clinical-stage biopharmaceutical company specializing in the discovery and development of a novel treatment for chronic inflammatory diseases. The candidate SOL-116 is a humanized antibody designed to provide efficacious therapy by blocking a previously overlooked target molecule (BSSL) of the immune system. The development is supported by solid pre-clinical data for rheumatoid arthritis. Lipum also explores other inflammatory diseases with a high unmet medical need.

Lipum AB (OSTO:LIPUM) Headlines

No Headlines